Review of NICE Technology Appraisal Guidance No. 124; Pemetrexed for the treatment of non-small-cell lung cancer, No. 162; Erlotinib for the second-line treatment of non-small-cell lung cancer and No. 175; Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal)

TA124 was issued in August 2007.  The review date for this guidance was January 2010.

TA162 was issued in November 2008.  The review date for this guidance was June 2010.

TA175 was issued in July 2009.  A review date for this guidance has not been defined.

The review date is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal. 

The Institute has carried out a search for information relevant to these appraisals, and believes that it is appropriate for the guidance to be updated; combining the three pieces of guidance into one Multiple Technology Appraisal (MTA).  The timing for the MTA should be based on when new data for erlotinib will become available in or around Q2 2012.

In order to be completely confident that this is appropriate, we are asking   consultees and commentators with an interest in this topic, to inform us of any evidence which would suggest that an earlier review would be beneficial.  We would particularly like to be made aware of timelines around on-going research, etc. which might affect the scheduling of this review should we go ahead with the proposal following this consultation. 

Please see appendix A for a full list of the organisations we have contacted.

June 2011